Do analysts rate BOLD or GALT?

Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 184.24%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galectin Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, BOLD or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.86 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A

Is BOLD or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% Galectin Therapeutics N/A N/A -176.83%

Do analysts recommend QTTB or BOLD?

Q32 Bio currently has a consensus price target of $32.17, suggesting a potential upside of 268.04%. Given Q32 Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Q32 Bio is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QTTB or BOLD more profitable?

Q32 Bio's return on equity of 50.17% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Boundless Bio N/A -70.89% -47.37%

Do analysts rate BOLD or IRON?

Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 82.18%. Given Disc Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Disc Medicine is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Disc Medicine 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77

Which has better earnings and valuation, BOLD or IRON?

Disc Medicine is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boundless Bio N/A N/A -$58.20M -$2.86 N/A Disc Medicine N/A N/A -$212.18M -$6.58 N/A

Is BOLD or IRON more profitable?

Disc Medicine's return on equity of -37.17% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% Disc Medicine N/A -37.17% -33.65%

Do analysts recommend BOLD or IPSC?

Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 229.86%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Century Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is BOLD or IPSC more profitable?

Century Therapeutics' return on equity of -49.51% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets Boundless Bio N/A -70.89% -47.37% Century Therapeutics N/A -49.51% -38.09%

Do analysts rate IFRX or BOLD?

InflaRx currently has a consensus price target of $7.43, suggesting a potential upside of 367.21%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.67 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IFRX or BOLD more profitable?

InflaRx's return on equity of -53.56% beat Boundless Bio's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Boundless Bio N/A -70.89% -47.37%

Boundless Bio (BOLD) Competitors

$2.43 -0.12 (-4.71%)

Closing price 04:00 PM Eastern

Extended Trading

$2.43 0.00 (0.00%)

As of 07:30 PM Eastern

Compare

BOLD vs. GALT, QTTB, IRON, IPSC, and IFRX

Should you buy Boundless Bio stock or one of its competitors? Boundless Bio's main competitors and comparable companies include Galectin Therapeutics (GALT), Q32 Bio (QTTB), Disc Medicine (IRON), Century Therapeutics (IPSC), and InflaRx (IFRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Boundless Bio compare to Galectin Therapeutics?

Boundless Bio (NASDAQ:BOLD) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, Galectin Therapeutics had 4 more articles in the media than Boundless Bio. MarketBeat recorded 5 mentions for Galectin Therapeutics and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.79 beat Galectin Therapeutics' score of 0.31 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Very Positive
Galectin Therapeutics	Neutral

Boundless Bio has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 184.24%. Given Galectin Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Galectin Therapeutics' return on equity of 0.00% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Galectin Therapeutics	N/A	N/A	-176.83%

11.7% of Galectin Therapeutics shares are held by institutional investors. 23.1% of Boundless Bio shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Galectin Therapeutics beats Boundless Bio on 10 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

31.3% of Q32 Bio shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Q32 Bio's return on equity of 50.17% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Boundless Bio	N/A	-70.89%	-47.37%

Q32 Bio currently has a consensus price target of $32.17, suggesting a potential upside of 268.04%. Given Q32 Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Q32 Bio is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Q32 Bio has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than Boundless Bio. Boundless Bio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.84	$29.82M	$3.00	2.91
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

In the previous week, Q32 Bio had 4 more articles in the media than Boundless Bio. MarketBeat recorded 5 mentions for Q32 Bio and 1 mentions for Boundless Bio. Boundless Bio's average media sentiment score of 1.79 beat Q32 Bio's score of 0.87 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Q32 Bio	Positive
Boundless Bio	Very Positive

Summary

Q32 Bio beats Boundless Bio on 14 of the 15 factors compared between the two stocks.

How does Boundless Bio compare to Disc Medicine?

Boundless Bio (NASDAQ:BOLD) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Boundless Bio has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Disc Medicine's return on equity of -37.17% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Disc Medicine	N/A	-37.17%	-33.65%

Disc Medicine is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

In the previous week, Boundless Bio and Boundless Bio both had 1 articles in the media. Boundless Bio's average media sentiment score of 1.79 beat Disc Medicine's score of 0.61 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Very Positive
Disc Medicine	Positive

Disc Medicine has a consensus target price of $110.18, suggesting a potential upside of 82.18%. Given Disc Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Disc Medicine is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

83.7% of Disc Medicine shares are held by institutional investors. 23.1% of Boundless Bio shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Disc Medicine beats Boundless Bio on 7 of the 12 factors compared between the two stocks.

How does Boundless Bio compare to Century Therapeutics?

Boundless Bio (NASDAQ:BOLD) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

50.2% of Century Therapeutics shares are held by institutional investors. 23.1% of Boundless Bio shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Boundless Bio and Boundless Bio both had 1 articles in the media. Boundless Bio's average media sentiment score of 1.79 beat Century Therapeutics' score of 0.46 indicating that Boundless Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Boundless Bio	Very Positive
Century Therapeutics	Neutral

Boundless Bio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

Century Therapeutics has higher revenue and earnings than Boundless Bio. Century Therapeutics is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A
Century Therapeutics	$109.16M	2.39	-$9.58M	-$0.93	N/A

Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 229.86%. Given Century Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Century Therapeutics is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics' return on equity of -49.51% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boundless Bio	N/A	-70.89%	-47.37%
Century Therapeutics	N/A	-49.51%	-38.09%

Summary

Century Therapeutics beats Boundless Bio on 10 of the 13 factors compared between the two stocks.

How does Boundless Bio compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 23.1% of Boundless Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

InflaRx's return on equity of -53.56% beat Boundless Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Boundless Bio	N/A	-70.89%	-47.37%

InflaRx has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market.

InflaRx currently has a consensus price target of $7.43, suggesting a potential upside of 367.21%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InflaRx has higher revenue and earnings than Boundless Bio. InflaRx is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	7,810.61	-$51.63M	-$0.58	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

In the previous week, InflaRx and InflaRx both had 1 articles in the media. Boundless Bio's average media sentiment score of 1.79 beat InflaRx's score of 0.91 indicating that Boundless Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
InflaRx	Positive
Boundless Bio	Very Positive

Summary

InflaRx beats Boundless Bio on 11 of the 14 factors compared between the two stocks.

Get Boundless Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLD vs. The Competition

Export

Metric	Boundless Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.01M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	9.71	193.11	18.97
Price / Sales	N/A	1,149.10	561.77	81.05
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.55	16.95	10.71	6.03
Net Income	-$58.20M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-5.45%	-4.83%	-3.18%	-3.04%
1 Month Performance	-14.13%	-12.20%	-6.61%	-5.16%
1 Year Performance	87.64%	8.87%	3.69%	-2.48%

Boundless Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLD Boundless Bio	1.2749 of 5 stars	$2.43 -4.7%	N/A	+102.4%	$58.01M	N/A	N/A	28	Positive News High Trading Volume
GALT Galectin Therapeutics	1.8004 of 5 stars	$3.64 +0.6%	$11.00 +202.2%	-18.0%	$238.40M	N/A	N/A	9
QTTB Q32 Bio	3.3441 of 5 stars	$8.09 +1.3%	$30.60 +278.2%	+144.8%	$237.86M	$53.74M	2.70	22	News Coverage Analyst Forecast
IRON Disc Medicine	2.5717 of 5 stars	$60.77 -0.7%	$110.18 +81.3%	-13.5%	$234.60M	N/A	N/A	165
IPSC Century Therapeutics	2.2583 of 5 stars	$1.46 +14.1%	$4.75 +225.3%	+153.2%	$231.78M	$109.16M	N/A	78	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLD) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boundless Bio (BOLD) Competitors

BOLD vs. GALT, QTTB, IRON, IPSC, and IFRX

How does Boundless Bio compare to Galectin Therapeutics?

Summary

How does Boundless Bio compare to Q32 Bio?

Summary

How does Boundless Bio compare to Disc Medicine?

Summary

How does Boundless Bio compare to Century Therapeutics?

Summary

How does Boundless Bio compare to InflaRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boundless Bio (BOLD) Competitors

BOLD vs. GALT, QTTB, IRON, IPSC, and IFRX

How does Boundless Bio compare to Galectin Therapeutics?

Does the media prefer BOLD or GALT?

Which has more volatility and risk, BOLD or GALT?

Do analysts rate BOLD or GALT?

Which has better valuation and earnings, BOLD or GALT?

Is BOLD or GALT more profitable?

Do institutionals and insiders have more ownership in BOLD or GALT?

Summary

How does Boundless Bio compare to Q32 Bio?

Do institutionals & insiders hold more shares of QTTB or BOLD?

Is QTTB or BOLD more profitable?

Do analysts recommend QTTB or BOLD?

Which has more risk and volatility, QTTB or BOLD?

Which has preferable valuation and earnings, QTTB or BOLD?

Does the media favor QTTB or BOLD?

Summary

How does Boundless Bio compare to Disc Medicine?

Which has more volatility & risk, BOLD or IRON?

Is BOLD or IRON more profitable?

Which has better earnings and valuation, BOLD or IRON?

Does the media refer more to BOLD or IRON?

Do analysts rate BOLD or IRON?

Do insiders & institutionals hold more shares of BOLD or IRON?

Summary

How does Boundless Bio compare to Century Therapeutics?

Do institutionals and insiders have more ownership in BOLD or IPSC?

Does the media prefer BOLD or IPSC?

Which has more risk & volatility, BOLD or IPSC?

Which has preferable valuation and earnings, BOLD or IPSC?

Do analysts recommend BOLD or IPSC?

Is BOLD or IPSC more profitable?

Summary

How does Boundless Bio compare to InflaRx?

Do insiders and institutionals hold more shares of IFRX or BOLD?

Is IFRX or BOLD more profitable?

Which has more volatility and risk, IFRX or BOLD?

Do analysts rate IFRX or BOLD?

Which has better valuation and earnings, IFRX or BOLD?

Does the media favor IFRX or BOLD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLD vs. The Competition

Boundless Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools